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Abstract
Purpose of review Endothelial dysfunction is intimately relat-
ed to the development of various cardiovascular diseases, in-
cluding hypertension, and is often used as a target for phar-
macological treatment. The scope of this review is to assess
effects of aspirin on endothelial function and their clinical
implication in arterial hypertension.
Recent findings Emerging data indicate the role of platelets in
the development of vascular inflammation due to the release
of proinflammatory mediators, for example, triggered largely
by thromboxane. Vascular inflammation further promotes ox-
idative stress, diminished synthesis of vasodilators,
proaggregatory and procoagulant state. These changes trans-
late into vasoconstriction, impaired circulation and thrombotic
complications. Aspirin inhibits thromboxane synthesis, abol-
ishes platelets activation and acetylates enzymes switching
them to the synthesis of anti-inflammatory substances.
Summary Aspirin pleiotropic effects have not been fully elu-
cidated yet. In secondary prevention studies, the decrease in
cardiovascular events with aspirin outweighs bleeding risks,
but this is not the case in primary prevention settings. Ongoing
trials will provide more evidence onwhether to expand the use
of aspirin or stay within current recommendations.
Keywords Aspirin . Endothelial function . Arterial
hypertension . Cyclooxygenase . Platelets . Inflammation
Introduction
Endothelium is of paramount importance for maintaining ho-
meostasis of cardiovascular system [1]. Healthy endothelium,
both in vasculature and heart chambers, is continuously re-
leasing plethora of bioactive substances. Acting in autocrine,
paracrine and systemic fashion and participating in regulation
of smooth muscle contractions, vascular wall permeability,
platelet aggregation, activation of coagulation and fibrinolytic
activity, cellular proliferation, as well as in prevention of in-
flammatory cells adhesion and vascular inflammation.
Imbalance between any of above functions is broadly defined
as endothelial dysfunction. To the different extent, most car-
diovascular diseases are classically attributed to endothelial
dysfunction (from atherosclerotic heart disease to rhythm dis-
turbances, e.g. atrial fibrillation) [2–4].
Given that endothelium takes part in regulation of vascular
tone, arterial hypertension and endothelial function are recip-
rocally and intimately associated with each other. However,
this association is far beyond simple imbalance between va-
sodilator and vasoconstrictor release in favour of the latter.
Multiple mechanisms are involved in regulation of blood pres-
sure, including the endothelium, kidneys and central regula-
tion [5].
Of note, the endothelium does not only provide short-term
effects on vascular tone. Endothelial dysfunction also has
chronic long-term consequences, which, in indirect way,
eventually have major impact on vascular remodelling and
blood pressure regulation. Oxidative stress, i.e. production of
free radicals outweighing their scavenging, is one of the sys-
temic pathological processes, related to endothelium.
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Inflammation in the vascular wall is another example, synthe-
sis of pro-inflammatory cytokines and recruitment of inflam-
matory cells, with hypertension being considered even as in-
flammatory disease now [5, 6].
Endothelial function has been extensively used as putative
target for pharmacological correction with drugs inhibiting
renin-angiotensin-aldosterone system, statins, antioxidants
and so on, but less attention was paid to vascular effects of
aspirin (i.e. acetylsalicylic acid) given its primary anti-
aggregatory mechanism of action. However, with the emerg-
ing evidence on role of platelets in inflammatory reactions and
immunomodulation, platelet inhibition with aspirin has been
found to also elicit also anti-inflammatory effects [7, 8, 9•, 10].
Moreover, aspirin was found to work as acetylating agent with
a range of beneficial effects on vascular endothelium beyond
platelet inhibition.
With regard to the possible effects of aspirin on blood pres-
sure and management of arterial hypertension, these will be
discussed in this review article.
Brief Overview of Aspirin Pharmacology: Inhibition
of Cyclooxygenase-1
Aspirin has been used for years as analgesic, antipyretic and
anti-inflammatory drug due to non-selective cyclooxygenase
(COX)-1 and COX-2 inhibition (historically at high doses).
Later, the major indication for aspirin shift to prevention of
thrombotic cardiovascular complications as anti-platelet drug
via predominant COX-1 inhibition within platelets, achiev-
able at low doses.
Cyclooxygenases are present in the endothelial cells and
tissues in two isoforms: COX-1 is considered to be a consti-
tutively expressed enzyme, assuring physiological functions
while COX-2 isoform is thought to carry potential for induc-
ibility, but it is expressed constitutively at lower levels too.
Cyclooxygenases are also defined as prostaglandin endoper-
oxide synthases or prostaglandin (Pg) G/H synthases since
first PgG2 is synthesised from the arachidonic acid by incor-
poration of oxygen molecules, then PgH2 is formed by reduc-
tion of PgG2. PgH2 is a substrate for enzymes, which via
isomerisation, reduction or other transformations produce
range of prostanoids. For example, thromboxane A2 (TxA2)
is synthesised by TxA2 synthase (TXAS) and prostacyclin
(PgI2) is synthesised by prostacyclin synthase (PGIS) [11].
These inhibitory effects of aspirin are determined by pres-
ence of acetyl group that leads to acetylation of serine hydrox-
yl group at position 529 in COX-1 with eventual irreversible
inhibition of the enzyme activity due to its inability to bind to
substrate, arachidonic acid. Inhibition of platelet-dependent
synthesis of TxA2 is accompanied by diminished release of
platelets granules, numerous chemokines, growth factors and
coagulation factors (Fig. 1) [7, 9•].
Many other ‘pleiotropic’ favourable effects of aspirin,
which are not directly related to inhibition of TxA2 synthesis,
are attributed to acetylation of target proteins. Their total num-
ber is far beyond half a thousand molecular targets, including
transcription factors, enzymes, genes, metabolites and so on
[12, 13•, 14].
The maximal plasma concentration of aspirin reaches
1 mg/L within half an hour for aspirin 100 mg taken orally
and 3 mg/L for aspirin 300 mg taken orally. These doses do
not inhibition of COX-2 with COX-1 inhibition being the net
pharmacological effect [8, 15]. Because of irreversible action
of aspirin (i.e. acetylation), duration of its effects is determined
by target protein resynthesis, that in case of mature platelets
lacking nuclei is equal to their lifetime (approximately
1 week). New platelets are needed in circulation to recover
TxA2 synthesis. The endothelial effects of aspirin are more
short lived as only few hours are required for endothelial cells
to restore their capacity for COX-1 regeneration [8].
Thromboxane A2 and Prostacyclin in Platelets
and Vasculature
Thromboxane A2 is synthesised via common pathway with
other prostanoids and is largely deposited in platelets, al-
though the non-platelet sources (e.g. leukocytes, endothelial
cells) exist (Fig. 1). Effects of TxA2 are mainly local and
realised in autocrine (i.e. platelet activation) and paracrine
(e.g. on endothelial cells, leukocytes and so on) manner rather
than systemic [8, 10, 11, 16, 17]. Multiple biological effects of
TxA2 are due to binding of TxA2 prostanoid (TP) receptors,
which are widely expressed in human body, including plate-
lets, endothelium and smooth muscle cells in vasculature and
myocardium [16]. Genetic polymorphism of TP receptors
may result in their hypo- or hyperreactivity [18]. Expression
of TP receptors on the cellular surface is enhanced in various
cardiovascular diseases. For example, in vessels affected by
atherosclerosis, there is a 3-fold increase of TP receptors den-
sity observed [19].
Activation of TP receptors on platelets leads to platelet
activation and further amplification of TxA2 synthesis and
release. Moreover, platelets α-granule content is released to
the blood flow that is represented by a multitude of biologi-
cally active molecules including coagulation, proinflammato-
ry and growth factors, adhesive receptors and so on (Fig. 1).
Following their release, these factors induce leukocytes re-
cruitment, formation of heterotypic aggregates (platelets–leu-
kocytes), promote inflammation, oxidative stress and remod-
elling of the vascular wall [7, 9•, 20–22].
Oxidative stress is prominent in cardiovascular diseases
including hypertension, and it typically leads to reduced NO
bioavailability and NO-dependent relaxation (Fig. 1) [23, 24].
Oxidative stress stimulates TxA2 pathway by TXAS upregu-
lation and reduced degradation of the immature form of TP
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receptors, thus stabilising them; vice versa, continuous signal-
ling via TP receptors leads to downstream generation of more
reactive oxygen species (ROS) [25–27]. Angiotensin II, the
major effector of the renin-angiotensin system not only pro-
motes hypertension, myocardial and vascular remodelling, but
it also contributes to activation of TxA2 synthesis and in-
creased expression of TP receptors either directly or through
nicotinamide adenine dinucleotide phosphate oxidase (NOX)
activation [28, 29].
Endothelial nitric oxide synthase (eNOS) uncoupling (via
oxidation of eNOS cofactor tetrahydrobiopterin) and dimin-
ished NO bioavailability are other well-recognised conse-
quences of oxidative stress in endothelium (Fig. 1).
Essentially, these processes lead to reduction of its vasodila-
tion, anti-aggregatory and anti-inflammatory effects and
exaggeration of above described changes [27]. Instead of
counterbalancing of vasoconstriction, platelet activation and
other pathological effects of TxA2, NOwhen exposed to ROS,
results in peroxynitrite formation. This was found to upregu-
late TxA2 synthesis and nitration of PGIS and promote platelet
activation [30, 31]. Platelet activation is also associated with a
release of thrombospondin-1 from α-granules that was shown
to diminish NO-dependent vasodilation in arteries via induc-
tion of ROS [32].
Thromboxane A2-triggered NOX also upregulates
phosphodiesterase type 4, which leads to hydrolysis of a
downstream mediator of prostacyclin, cyclic adenosine
monophosphate (cAMP), reducing its favourable vaso-
protective and vasodilatory effects [33]. At a background of
oxidative stress 8-isoprostane (PgF2α) is synthesised in
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Fig. 1 Influence of aspirin on endothelial function. * Various re-
ceptors participate in cellular interactions. 15R-HETE, 15-
Hydroxyeicosatetraenoic acid; 5-HT, serotonin; 5-LOX , 5-
lipooxygenase; AA, arachidonic acid; AC, adenylate cyclase; IP,
prostacyclin receptor; ADP, adenosine diphosphate; ALX, ATL receptor;
ASA, acetyl salicylic acid; Ac, acetyl group;ATL, aspirin-triggered 15-epi-
lipoxin A4; ATP, adenosine triphosphate; cAMP, cyclic adenosine
monophosphate; cGMP, cyclic guanosine monophosphate; COX,
cyclooxygenase; CXCL1, 4, 5, 7, 8, 12, chemokine (C-X-C motif) ligand
1, 4, 5, 7, 8 and 12, respectively; EDHF, endothelium-derived
hyperpolarising factor; EGF, epidermal growth factor; eNOS, endothelial
nitric oxide synthase; FV, XI, XIII, coagulation factors V, XI, XIII,
respectively; FGF, fibroblast growth factor; GPVI, collagen receptor;
GTP, guanosine triphosphate; HO-1, heme oxygenase 1; IGF, insulin-
like growth factor; IL-1β, interleukin-1β; IL-6, interleukin-6; MCP-1,
monocyte chemoattractant protein 1;MIP-1α, macrophage inflammatory
protein 1α;MMP-1, 2, 9, matrix metalloproteinase 1, 2 and 9, respective-
ly; mRNA, matrix ribonucleic acid; NO, nitric oxide; NOX, nicotinamide
adenine dinucleotide phosphate-oxidase; PDGF, platelet-derived growth
factor; PgG2/H2, prostaglandin G2/H2; PgI2, prostacyclin; PGIS,
prostacyclin synthase; PSGL-1, P-selectin glycoprotein ligand 1;
RANTES, regulated on activation, normal T Cell expressed and secreted;
S1P, phingosine-1-phosphate; S1P2, S1P receptor 2; sGC, soluble
guanylate cyclase; SMC, smooth muscle cell; TGF-β1, transforming
growth factor beta 1; TIMP-1, 4, tissue inhibitor of MMP 1 and 4,
respectively; TNF-α, tumour necrosis factor α; TP, thromboxane
prostanoid receptor; TSP-1, thrombospondin 1; TxA2, thromboxane A2;
TXAS, thromboxane A2 synthase; VEGF, vascular endothelial growth
factor; vWF, von Willebrand factor
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increased amount and may serve as TP receptor ligand, caus-
ing similar to TxA2 downstream effects [34]. Selective block-
ade of NOX, on the contrary, is associated with decrease in
TxA2, and it improves vasodilatory response in arteries [35].
Apart from ROS-mediated decrease in NO, stimulation of
TP receptors also inhibits endothelial NO production via di-
rect suppression of eNOS phosphorylation [36]. This relation-
ship appears to be reciprocal, as inhibition of NO production,
e.g. with L-NAME (NG-methyl-L-arginine acetate ester), acti-
vates aggregation of platelets [37]. Consequently, NO within
platelets is involved in regulation of platelet activation and
aggregation (Fig. 1). The mechanisms involved are not entire-
ly clear, and they are at least partly mediated by a NO-
dependent release of calcium from the platelet dense granules.
Reduction in NO levels causes accumulation of calcium in
platelets cytoplasm. This triggers TxA2 synthesis from the
arachidonic acid located within the platelet membrane phos-
pholipids. Interestingly, Banerjee et al. showed that decreased
NO synthesis in platelets was a convergent point in platelet
activation pathway irrespectively of an activating agent via
various platelet receptors (i.e. adenosine diphosphate, colla-
gen, thrombin or epinephrine) [38].
Endothelium-dependent hyperpolarisation, another impor-
tant mechanism of vasodilation and regulation of the blood
flow, is also interfered with TxA2 due to its involvement in
modulation of Ca2+-activated potassium channels [39].
Moreover, it impairs signal propagation through gap junctions
within endothelial layer and smooth muscle cells that affects
endothelium dependent hyperpolarisation and vasodilation
(Fig. 1) [39].
In line with NO-dependent mechanisms and endothelium-
dependent hyperpolarisation, prostacyclin counteracts the
vasocontracting factors, like as TxA2 and other prostanoids,
endothelin I, angiotensin II, etc. Prostacyclin can be synthe-
sised both in endothelial cells and vascular smooth muscle
cells, and it is the most abundant prostaglandin among other
prostanoids. Similarly to TxA2, prostacyclin works locally,
and then metabolised to 6-keto-PgF1α. Prostacyclin effects
are realised via prostacyclin receptors (IP), which are also
have widely distributed in tissues (Fig. 1) [11, 40, 41].
There are also two competing points of view whether
COX-1 or COX-2 is the main isotype contributing to prosta-
cyclin synthesis [11, 40, 42, 43]. This question has been ex-
tensively discussed, since a decrease in prostacyclin levels has
long been considered as the main cause of adverse cardiovas-
cular events associated with COX-2 selective inhibitors [44].
Indeed, selective COX-2 depletion in vascular smooth muscle
cells and endothelial cell in mice decreased prostacyclin
levels, which was associated with blood pressure elevation
and accelerated atherogenesis [45]. However, recent data fa-
vour COX-1, as the source of prostacyclin synthesis in
vasculature both under basal conditions and stimulation with
shear stress or pharmacologically [43, 46, 47].
These data may provide some insights into the mechanisms
of hypertension. Simplistically, hypertension occurs when
endothelium-dependent vasoconstriction outweighs vasore-
laxation, due to either decreased production of endothelium-
derived relaxing factors or increased production of
endothelium-derived contractile factors, or both [5].
Obviously, pathogenesis of hypertension is complex and this
is only one of the multiple pathways involved.
Interplay between mediators, receptors and cellular envi-
ronment is also complex. This can be illustrated by the pros-
tacyclin effects on vasculature. COX-1 is likely to be the main
source of prostacyclin synthesis; however, COX-2 is likely to
input towards the prostacyclin pool, particularly in various
conditions known to be associated with endothelial dysfunc-
tion, e.g. arterial hypertension, atherosclerosis, diabetes
mellitus and aging [43, 48, 49]. Also patterns of enzymes
and receptors expression may vary, depending on setting.
In terms of signalling via TxA2 receptors and intermediate
metabolite in prostanoi synthesis, PgH2 were considered as
major drivers of endothelium-dependent contraction, while
NO and prostacyclin as potent relaxing factors. However,
prostacyclin was yielded to serve as a contracting agent as
well, when binding to TP receptors rather than to IP receptors
(Fig. 1) [40, 41]. This appears to happen when IP receptors are
getting dysfunctional, e.g. in cardiovascular diseases associat-
ed with endothelial dysfunction. Compensatory increase in
prostacyclin synthesis in these settings (previously considered
as protective mechanism) [50] results in more prostacyclin
bound to TP receptors [41, 51]. For example, Liu et al. ob-
served contraction of mice aorta, the effect that was eliminated
either at a receptor level (via inhibition of TP receptors) or by
reduction of prostacyclin synthesis via COX-1 knockout at a
background of low TxA2 synthesised [52].
Reduced NO release further exaggerates the imbalance
[53]. Under physiological conditions, when sufficient NO is
available, prostacyclin produces IP receptors-mediated vaso-
dilation. In contrast, when NO availability is low, signalling
via TP receptors is triggered by prostacyclin [40, 41, 43].
Given that expression of eNOS in hypertension in endotheli-
um is reduced, prostacyclin is prone to trigger signalling via
TP receptors [49].
Thromboxane A2 Inhibition: Cyclooxygenase-1 Versus
Target-Specific Drugs
Platelet aggregation is part of maintenance of haemostasis and
homeostasis. Nonetheless, in cardiovascular diseases, linked to
endothelial damage, platelet functioning exceeds physiological
range and risk of thrombotic complications increases [54]. In
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clinical practice, aspirin is the most commonly used antiplatelet
agent for prevention of adverse events in patients with cardio-
vascular or cerebrovascular disease [55]. Preventive effect is
achieved via inhibition of platelet activation and aggregation
due to inhibition of TxA2 synthesis. Apparently, one can also
anticipate breaking the vicious cycle of TxA2-mediated platelet
activation, oxidative stress, vascular inflammation, eNOS
uncoupling and reduced NO bioavailability with TxA2 inhibi-
tion. Resulting effects are essentially beneficial for vascular
function irrespectively of the nature of disease, e.g. coronary
artery disease, hypertension, or arrhythmia.
Indeed, taking into account consequences of activations of
TP receptors, their inhibition could be clinically beneficial.
Several drugs were developed to avoid side effects associated
with COX-1 inhibition, but to retain beneficial effects of TP
signalling interruption [56, 57]. A selective inhibitor of TXAS
synthase and TP receptor antagonist (BM-573) was tested in
apolipoprotein E knockout mice, a model of atherosclerosis
associated with reduced endothelium-derived relaxation and
NO bioavailability, enhanced oxidative stress and blood pres-
sure elevation. The treatment led to improvement in all of the
above parameters [56]. Reduction in blood pressure and
abolished atherosclerosis progression were also observed in
other experimental studies of TP antagonists [28, 58, 59].
Terutroban (S18886) is perhaps the best known TP receptor
antagonist. In animal studies, terutroban showed ability to
reduce NOX upregulation and ROS production [60], improve
endothelial function [36] and attenuate renal damage in hyper-
tension [61]. In spontaneously hypertensive stroke-prone rats,
the use of terutroban prevented cell proliferation in the vessel
media, abolished accumulation of collagen and fibronectin in
the vascular wall and inhibited expression of heat shock pro-
tein-47, MCP-1 and transforming growth factor 1β [62, 63].
Although in some experiments effects of terutroban on in-
flammation and endothelial function even outweighed effects
of aspirin [63], positive effects of TP receptors blockade ob-
tained in animal models did not translate into better outcomes
in humans [64]. In the PERFORM trial (Prevention of cere-
brovascular and cardiovascular Events of ischaemic origin
with teRutroban in patients with a history oF ischaemic
strOke or tRansient ischaeMic attack), there was a similar rate
of primary end-point of fatal or non-fatal ischaemic stroke,
fatal or non-fatal myocardial infarction, or other vascular
death observed in terutroban and aspirin groups (11 vs.
11 %, hazard ratio (HR) 1.02, 95 % confidence interval (CI)
0.94–1.12) and increased risk of minor bleeding in terutroban
arm (12 vs. 11 %, HR 1.11, 95 % CI 1.02–1.21) [64]. The trial
was stopped prematurely. There was also no difference in
carotid atherosclerosis progression, assessed by carotid
intima-media thickness measurements and carotid plaques be-
tween the two treatment groups [65]. Nonetheless, despite the
lack of clinical success so far, selective inhibition of TxA2,
either by synthesis or TP receptors or both, remains one of
attractive pharmacological targets in cardiology [56, 57].
Aspirin and Endothelial Function: Beyond Thromboxane
A2 Inhibition
What makes the difference between aspirin and selective
TxA2 inhibition given controversies between animal and bed-
side data? One explanation is that dual inhibition, TXAS and
TP receptors is required because the latter can be activated by
other substances, e.g. isoprostanes [56]. Obviously, the more
pathways of platelets activation are blocked, the higher effec-
tiveness of treatment is expected in relation to both clinical
outcomes and endothelial function [66, 67]. Also, aspirin has a
plethora of favourable vascular effects in addition to modula-
tion of the COX-1-dependent TxA2 synthesis and platelet ac-
tivation, which will be discussed below. Noteworthy, decrease
in prostacyclin synthesis in endothelium, due to COX-1 inhi-
bition, was thought to be an unfavourable effect of aspirin,
now in light of emerging role of prostacyclin in TP receptor
signalling is considered to be advantageous [48]. It was also
discovered that IP and TP receptors were capable of formation
of heterodimeric receptor complex. Within such complex bi-
ological downstream effects of TP receptors can shift towards
those realised via IP receptors stimulation [68].
Endothelial Nitric Oxide Synthase Acetylation
Aspirin was found to acetylate lysine of eNOS, which evokes
activation of its enzymatic activity, i.e. NO synthesis, release
and bioavailability of NO not only in endothelial cells, but
also in platelets (Fig. 1). Moreover, this effect appeared to be
independent of COX-1 inhibition and TxA2 production
[69–72]. Obviously, in platelets pre-treated with aspirin,
TxA2 level is reduced; thus, their activation is prevented by
modulation of both pathways, and downstream decrease in
platelet-mediated inflammation in vascular wall can be ex-
pected [38, 73].
Two small clinical trials assessed the effect of various doses
of aspirin, ranging 81 to 1300 mg, on NO production in pa-
tients with metabolic syndrome and coronary artery disease.
NO production was indirectly assessed based on levels of
heme-oxygenase-1 (HO-1), which is known to be upregulated
with increased NO production, and asymmetrical
dimethylarginine (ADMA), that serves as eNOS inhibitor.
These biomarkers were measured at baseline and after
12 weeks of the treatment. In both primary and secondary
prevention cohorts, aspirin increase in HO-1 and decrease in
ADMA indicate its ability to increase NO production [74, 75].
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Aspirin-Triggered Lipoxins and Resolvins
Lipoxins are a type of lipid mediators generated from arachi-
donic acid. Following aspirin intake, COX-2 is acetylated that
switches its enzymatic activity from a prostaglandin endoper-
oxide synthase to a lipoxygenase pathway (Fig. 1). First, in-
termediate 15(R)-hydroxyeicosatetraenoic acid is synthesised,
then it is converted to ATL by 5-, 12-, or 15-lipoxygenases in
various cell types (e.g. endothelial cells, platelets and leuko-
cytes) to 15R-epimers of intrinsic lipoxin A4 and B4, defined
as 15-epi-lipoxins or aspirin-triggered lipoxins (ATL) [76, 77].
Aspirin-triggered lipoxins are considered to be more potent
than intrinsic lipoxins with effects mediated via appropriate
receptor lipoxin A4 receptor (ALX) / formyl peptide receptor
(FPR2) with high affinity to it [76, 77]. Aspirin-triggered
lipoxins are capable of reduction of NOX-mediated endothe-
lial production of ROS via suppression of redox-sensitive ac-
tivation of the transcriptional factor nuclear factor-kappa B,
induced by either angiotensin II, tumour necrosis factor-α, or
thrombin [78]. Aspirin-triggered lipoxins also block platelet-
derived growth factor-stimulated proliferation and migration
of smooth muscle cells in vasculature [79]. ATL were shown
to reduce adhesion of human leukocytes to endothelial cells,
reducing inflammation within the vascular wall [80, 81].
Given the role platelets play in regulation of leukocytes adhe-
sion to vascular endothelium, lipoxins released by platelet–
leukocyte aggregates control leukocyte activation and adhe-
sion and reduce damage to the vascular wall [82]. Noteworthy,
ATL levels were found to be reduced in patients with athero-
sclerotic lesions, particularly in patients with advanced athero-
sclerosis [79].
Resolvins (resolution phase interaction products) represent
another group of substances with potent anti-inflammatory
properties. Resolvins are synthesised from docosohexaenoic
and eicosopentaenoic omega-3 polyunsaturated fatty acids
(PUFA); hence, PUFA supplementation was found to restore
resolvins level if decreased in cardiovascular disease [83].
For example, resolvin E1 (RvE1) is generated by the trans-
formation of 18R-hydro (peroxy)-eicosapentaenoic acid,
which in turn is synthesised by the aspirin-acetylated COX-2
in endothelium. Resolvin E1 inhibits transmigration and infil-
tration of polymorphonuclear leukocytes in vascular wall as
well as formation of platelet aggregates [84]. Significant de-
crease of expression of pro-inflammatory cytokines and adhe-
sion molecules, increase in RvE1 level and, interestingly, de-
crease in blood pressure were observed in mice treated with
fish oil (as source of PUFA) and aspirin [85].
Sphingosine-1 Phosphate
Lysosphingolipid sphingosine-1 phosphate (S1P) is another
mediator released from platelets in large quantities upon acti-
vation, during thrombus formation and inflammation. Given
that the S1P release is promoted by TxA2, aspirin indirectly
inhibits S1P signalling (Fig. 1). Sphingosine-1 phosphate is
produced via two isoforms of sphingosine kinase (SphK), of
which SphK2 is predominant in platelets, and then binds to
S1P receptors on endothelial cells and smooth muscle cells
[86].
Circulating S1P may confer protective signalling for vas-
culature by taking part in maintenance of endothelial layer
integrity, reduction in expression of adhesion molecules in
endothelium and inhibition of leukocyte adhesion to the en-
dothelium, and increase NO production (mostly via S1P1 re-
ceptor). On the contrary, opposing effects are triggered by
high levels of S1P released locally from the activated platelets
(via S1P2 receptor) [87].
Clinical Implications of Aspirin Use in Hypertension
Impact of Aspirin on Vasculature and Blood Pressure:
Bedside Data
Few studies addressed impact of aspirin on vascular function
and blood pressure in patients with arterial hypertension.
Moreover, the studies were generally small and heterogeneous
in term of the studies population, concomitant drugs use, as-
pirin dose, duration of treatment and generally had small num-
bers. For example, Pietri et al. assessed effect of 160 mg of
aspirin administered for 2 weeks, on blood pressure and pa-
rameters of arterial stiffness in a small group, of untreated
patients with mild hypertension. They observed 0.5 m/s re-
duction in pulse wave velocity in the aspirin arm of the study
(which they reasonably attributed to endothelial function and
vascular tone), and there were no changes found in placebo
arm. There was no significant decrease in blood pressure as
well [88]. Another study, with similar aspirin dosing and du-
ration of treatment, showed improvement in flow-mediated
dilation and decrease in C-reactive protein and intercellular
adhesion molecules level with aspirin. However, due to the
study design, it was impossible to reliably separate effects of
aspirin from effects of concomitant treatments [89]. In another
study, aspirin therapy resulted in improvement of flow-
mediated dilation and blood pressure reduction, when com-
bined with statins, while no significant dynamics was ob-
served on aspirin monotherapy [90].
The impact of aspirin on blood pressure was found to de-
pend on the time of administration and also to differ in males
and females. Hermida et al. performed a series of studies that
addressed time-dependent effect of low-dose aspirin (100 mg)
administration. Interestingly, a 3-month course of treatment
resulted in a minor but significant reduction of ambulatory
blood pressure when patients received aspirin at bedtime rath-
er than at awakening, both in mild hypertension and pre-
hypertension states [91–94]. The effect was consistent across
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patients subgroups, but particularly pronounced in females
and non-dippers [93, 94].
Overall, robust clinical data on effects of aspirin on vascu-
lar function and blood pressure control are scarce, which pre-
vents reliable conclusion on clinical significance of these
effects.
Prevention of Cardiovascular and Cerebrovascular Events
Despite high blood pressure values being the major cause of
vascular complications per se, duration of hypertension, par-
ticularly when poorly controlled, is associated with ‘silent’
endothelial damage that in turn hastens atherosclerosis pro-
gression [1, 4]. Thus, patients with no clinically apparent cor-
onary artery disease may have their first manifestation of
CAD as acute one, e.g. acute coronary syndrome [54].
Despite multiple effects of aspirin that in theory can reduce
blood pressure, it is not clinically used for blood pressure
lowering. However, given that in management of patients with
arterial hypertension, prevention of adverse cardiovascular
events is crucial, many hypertensive patients use the agent.
Aspirin has a large body of evidence favouring its use for
the secondary prevention, but use of aspirin for primary pre-
vention remains controversial. Recent European guidelines on
cardiovascular disease prevention did not support prophylac-
tic use of aspirin in individuals without established cardiovas-
cular disease because the risk of major bleeding outweighs the
minor decrease in rate of major adverse cardiac events [55].
However, European guidelines for the management of arterial
hypertension suggested consideration of aspirin use for prima-
ry prevention in patient with high cardiovascular risk or re-
duced kidney function based on more balanced risk-benefit
profile in these categories of patients [95].
The US Preventive Services Task Force has also recently
updated recommendations on the use of aspirin for the prima-
ry prevention of cardiovascular disease and colorectal cancer.
Low-dose aspirin is now supported in men and women aged
50 to 59 years who have a predicted risk for myocardial in-
farction or stroke of at least 10 % over 10 years, with no
elevated bleeding risk, and willing to take aspirin within
10 years or longer. In patients aged 60 to 69 years, a decision
has to be made on an individual basis. Other age groups were
omitted in the document because of the lack of evidence [96].
Broadly, similar principles were incorporated in the recom-
mendations for antiplatelet treatment for primary prevention
of cardiovascular disease in the UK. Age over 50 years with a
high cardiovascular risk, defined as 10 years risk of greater
than 20 %, or reduced renal function (e.g. estimated glomer-
ular filtration rate less than 45 mL/min/1.73 m2) are the clin-
ical scenarios, when aspirin treatment in patients with hyper-
tension can be recommended [97].
There is also controversy in relation to aspirin use in primary
prevention settings in patients with diabetes, which is closely
linked to other cardiovascular risk factors and cardiovascular
morbidity, including hypertension and coronary artery disease.
Diabetes is known to be associated with persistent TxA2-de-
pendent platelet activation [98]. In diabetic patients, aspirin use
showed a significant 10 % reduction of risk of major adverse
cardiovascular events, with no effect on myocardial infarction,
stroke, cardiovascular or all-cause mortality, and a trend to-
wards higher rate of gastrointestinal bleeds [99].
Despite relation between hazards and benefits of aspirin for
primary prevention remained broadly stable with adding new
clinical trials to meta-analyses (Table 1), update for evidence
is still needed at least because of the following reasons.
Widespread use of statins for primary prevention needs to be
accounted for as well improving control of cardiovascular risk
factors, e.g. hypertension itself, smoking and obesity. These
factors can modulate the overall net benefits of aspirin for
primary prevention, and they need to be accounted for future
analyses.
Ongoing Trials
There are several on-going trials on the utility of aspirin in
primary prevention settings. The ARRIVE (Aspirin to Reduce
Risk of Initial Vascular Events) study aims to evaluate the
efficacy and tolerability of 100 mg enteric-coated aspirin com-
pared to placebo in patients with no history of established
cardiovascular disease and moderate risk of major coronary
heart disease events for the prevention of cardiovascular dis-
ease events, including myocardial infarction, unstable angina,
stroke or transient ischaemic attack, as well as cardiovascular
death [107]. In the ASPREE (Aspirin in Reducing Events in
the Elderly) trial effects of 100 mg enteric-coated aspirin on
the composite primary endpoint, defined as ‘disability-free
life’, including onset of dementia, all-cause mortality, or per-
sistent disability in at least one of the Katz Activities are
assessed in individuals free of dementia, disability and cardio-
vascular disease [108].
There are also two ongoing trials, addressing aspirin for
primary prevention in diabetic patients, who are known to be
particularly prone to develop atherosclerosis and coronary ar-
tery disease, but based on current guidelines should not take
aspirin for primary prevention [55]. The ACCEPT-D (Aspirin
and Simvastatin Combination for Cardiovascular Events
Prevention Trial in Diabetes) assesses efficacy of aspirin,
added to simvastatin in patients with either type I or type II
diabetes mellitus on development of the primary combined
end-point of cardiovascular death, non-fatal myocardial in-
farction, non-fatal stroke and hospital admission for cardio-
vascular causes, including acute coronary syndrome, transient
ischemic attack, not planned revascularization procedures, pe-
ripheral vascular disease [109]. In the ASCEND (A Study of
Cardiovascular Events iN Diabetes), patients are randomised
to aspirin and/or omega-3 fatty acid for the primary prevention
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of cardiovascular events [110]. Finally, the TIPS-3
(International Polycap Study 3) trial will assess effect of com-
bination of enteric-coated aspirin and cholecalciferol versus
placebo on the composite end point of major cardiovascular
disease (cardiac death, non-fatal stroke, non-fatal myocardial
infarction), plus heart failure, resuscitated cardiac arrest, or
revascularization with evidence of ischemia; aspirin versus
placebo on composite of cardiovascular events (cardiac death,
myocardial infarction or stroke) and cancer as well as risk of
fractures against a cholecalciferol therapy [111]. These new
studies would hopefully optimise utilisation of aspirin for pri-
mary prevention and identify patients groups who are likely to
benefit from such treatment.
High On-treatment Platelet Reactivity
High-on-treatment platelet reactivity (or less appropriately
termed as aspirin resistance) refers to failure of aspirin to pre-
vent cardiovascular events [112]. It is less related to use of
aspirin in hypertension because of limited indications in this
group of patients, but representing an important phenomenon
of aspirin, platelets and endothelial dysfunction interplay. Such
patients were found to have approximately four time higher risk
of cardiovascular events, compared to patients with low resid-
ual platelet reactivity [113, 114]. It is often explained by insuf-
ficient inhibition of TxA2 synthesis in platelets; however, pre-
cise mechanisms have not been fully elucidated, yet [115].
First, platelets are activated via multiple pathways and re-
ceptors, among which aspirin targets only one. Multiple studies
showed substantial decrease in TxB2 level, reflecting dimin-
ished TxA2 synthesis; however, applying COX-1 functional
testing, as a reliable measure for residual platelet reactivity
and prognostication of cardiovascular outcomes, remained con-
troversial [17, 112, 116–119]. Second, non-platelet sources of
TxA2 generation should be considered, specifically, endotheli-
um and monocytes/macrophages [8, 10, 120]. Therefore, usual
once a day dosing regimen may be less effective to assure
continuous inhibition of TxA2 synthesis [121, 122]. Third, en-
vironment in vasculature seems to play important role, e.g.
oxidative stress, inflammation, NO synthesis as well as patient
characteristics which are causative of the former like as
smoking, obesity and diabetes mellitus [9•, 123, 124•, 125•].
For example, brachial flow-mediated dilation was found to be
inversely associated with platelet adhesion and aggregation
[124•]. Also, immature reticulated platelets were found to be
less suppressed by antiplatelet drugs [126].
Conclusions
Aspirin has been introduced into clinical practice more than a
century ago, and its use is supported by large body of evi-
dence, e.g. for secondary prevention of cardiovascular events.Ta
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Despite this, it is increasingly acknowledged that the multi-
tude of actions of aspirin is not fully elucidated yet. Ongoing
trials may spread current use of aspirin to new areas, which are
now considered largely controversial. Notwithstanding pleio-
tropic effects of aspirin on endothelial function, it is unlikely
that we will start using aspirin as an antihypertensive agent;
however, this may bring additional clinical benefits in selected
patients with hypertension, for primary prevention of adverse
cardiovascular events.
Compliance with Ethical Standards
Conflict of Interest Drs. Dzeshka, Shantsila, and Lip declare no con-
flicts of interest relevant to this manuscript.
Human and Animal Rights and Informed Consent This article does
not contain any studies with human or animal subjects performed by any
of the authors.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
Papers of particular interest, published recently, have been
highlighted as:
• Of importance
1. Cahill PA, Redmond EM. Vascular endothelium—gatekeeper of
vessel health. Atherosclerosis. 2016;248:97–109.
2. Deshko MS, Snezhitsky VA, Dolgoshey TS, Madekina GA,
Stempen TP. Flow-mediated dilation in patients with parox-
ysmal atrial fibrillation: initial evaluation, treatment results,
pathophysiological correlates. Europace : Eur, Arrhythmias,
Cardiac Electrophysiol: J Working Groups Cardiac Pacing,
Arrhythmias, Cardiac Cell Electrophysiol Eur Soc Cardiol.
2011;13(suppl 3).
3. Kornej J, Apostolakis S, Bollmann A, Lip GY. The emerging role
of biomarkers in atrial fibrillation. Can J Cardiol. 2013;29(10):
1181–93.
4. Lehoux S, Jones EA. Shear stress, arterial identity and atheroscle-
rosis. Thromb Haemost. 2016;115(3):467–73.
5. Brandes RP. Endothelial dysfunction and hypertension.
Hypertension. 2014;64(5):924–8.
6. De Miguel C, Rudemiller NP, Abais JM, Mattson DL.
Inflammation and hypertension: new understandings and poten-
tial therapeutic targets. Curr Hypertens Rep. 2014;17(1):1–10.
7. Schrottmaier WC, Kral JB, Badrnya S, Assinger A. Aspirin and
P2Y12 inhibitors in platelet-mediated activation of neutrophils
and monocytes. Thromb Haemost. 2015;114(9):478–89.
8. Muller KA, Chatterjee M, Rath D, Geisler T. Platelets, inflamma-
tion and anti-inflammatory effects of antiplatelet drugs in ACS
and CAD. Thromb Haemost. 2015;114(3):498–518.
9.• Thomas MR, Storey RF. The role of platelets in inflammation.
Thromb Haemost. 2015;114(9):449–58. Comprehensive review
of the role of platelets in inflammation.
10. Hohlfeld T, Schrör K. Antiinflammatory effects of aspirin in ACS:
relevant to its cardiocoronary actions? Thromb Haemost.
2015;114(9):469–77.
11. Feletou M, Huang Y, Vanhoutte PM. Endothelium-mediated con-
trol of vascular tone: COX-1 and COX-2 products. Br J
Pharmacol. 2011;164(3):894–912.
12. Alfonso L, Ai G, Spitale RC, Bhat GJ. Molecular targets of aspirin
and cancer prevention. Br J Cancer. 2014;111(1):61–7.
13.• Dai SX, Li WX, Li GH, Huang JF. Proteome-wide prediction of
targets for aspirin: new insight into the molecular mechanism of
aspirin. Peer J. 2016;4:e1791.An analysis showing multiple tar-
gets for aspirin.
14. Serebruany VL, Cherepanov V, Cabrera-Fuentes HA, Kim MH.
Solid cancers after antiplatelet therapy: confirmations, controver-
sies, and challenges. Thromb Haemost. 2015;114(12):1104–12.
15. Nagelschmitz J, Blunck M, Kraetzschmar J, Ludwig M, Wensing
G, Hohlfeld T. Pharmacokinetics and pharmacodynamics of
acetylsalicylic acid after intravenous and oral administration to
healthy volunteers. Clin Pharmacol: Adv Appl. 2014;6:51–9.
16. Smyth EM. Thromboxane and the thromboxane receptor in car-
diovascular disease. Clin Lipidol. 2010;5(2):209–19.
17. Petrucci G, Rizzi A, Cavalca V, Habib A, Pitocco D, Veglia F,
et al. Patient-independent variables affecting the assessment of
aspirin responsiveness by serum thromboxane measurement.
Thrombosis Haemostasis. 2016(2016-07-21 00:00:00).
18. Gleim S, Stitham J, TangWH, Li H, Douville K, Chelikani P, et al.
Human thromboxane A2 receptor genetic variants: in silico,
in vitro and "in platelet" analysis. PLoS ONE. 2013;8(6), e67314.
19. Katugampola SD, Davenport AP. Thromboxane receptor density
is increased in human cardiovascular disease with evidence for
inhibition at therapeutic concentrations by the AT(1) receptor an-
tagonist losartan. Br J Pharmacol. 2001;134(7):1385–92.
20. Blair P, Flaumenhaft R. Platelet α–granules: basic biology and
clinical correlates. Blood Rev. 2009;23(4):177–89.
21. Koenen RR. The prowess of platelets in immunity and inflamma-
tion. Thrombosis Haemostasis. 2016(2016-07-07 00:00:00).
22. Soon ASC, Chua JW, Becker DL. Connexins in endothelial barrier
function – novel therapeutic targets countering vascular
hyperpermeability. Thrombosis Haemostasis. 2016(2016-08-04
00:00:00).
23. Pierini D, Bryan NS. Nitric oxide availability as a marker of oxi-
dative stress. Methods Mol Biol (Clifton, NJ). 2015;1208:63–71.
24. Higashi Y, Maruhashi T, Noma K, Kihara Y. Oxidative stress and
endothelial dysfunction: clinical evidence and therapeutic impli-
cations. Trends Cardiovasc Med. 2014;24(4):165–9.
25. Ball SK, Field MC, Tippins JR. Regulation of thromboxane re-
ceptor signaling at multiple levels by oxidative stress-induced sta-
bilization, relocation and enhanced responsiveness. PLoS ONE.
2010;5(9), e12798.
26. Muzaffar S, Shukla N, Massey Y, Angelini GD, Jeremy JY.
NADPH oxidase 1 mediates upregulation of thromboxane A2
synthase in human vascular smooth muscle cells: inhibition with
iloprost. Eur J Pharmacol. 2011;658(2–3):187–92.
27. Zhang M, Song P, Xu J, Zou MH. Activation of NAD(P)H oxi-
dases by thromboxane A2 receptor uncouples endothelial nitric
oxide synthase. Arterioscler Thromb Vasc Biol. 2011;31(1):125–
32.
28. Francois H, Athirakul K, Mao L, Rockman H, Coffman TM. Role
for thromboxane receptors in angiotensin-II-induced hyperten-
sion. Hypertension. 2004;43(2):364–9.
29. Sparks MA, Makhanova NA, Griffiths RC, Snouwaert JN, Koller
BH, Coffman TM. Thromboxane receptors in smooth muscle
Curr Hypertens Rep (2016) 18: 83 Page 9 of 12 83
promote hypertension, vascular remodeling, and sudden death.
Hypertension. 2013;61(1):166–73.
30. Schildknecht S, van der Loo B, Weber K, Tiefenthaler K, Daiber
A, Bachschmid MM. Endogenous peroxynitrite modulates
PGHS-1-dependent thromboxane A2 formation and aggregation
in human platelets. Free Radic Biol Med. 2008;45(4):512–20.
31. Zou MH. Peroxynitrite and protein tyrosine nitration of prostacy-
clin synthase. Prostaglandins LipidMediators. 2007;82(1–4):119–
27.
32. Nevitt C,McKenzie G, Christian K, Austin J, Hencke S, Hoying J,
et al. Physiological levels of thrombospondin-1 decrease NO-
dependent vasodilation in coronary microvessels from aged rats.
Am J Physiol Heart Circ Physiol. 2016;310(11):H1842–H50.
33. Muzaffar S, Jeremy JY, Angelini GD, Shukla N. NADPH oxidase
4 mediates upregulation of type 4 phosphodiesterases in human
endothelial cells. J Cell Physiol. 2012;227(5):1941–50.
34. Lassegue B, San Martin A, Griendling KK. Biochemistry, physi-
ology, and pathophysiology of NADPH oxidases in the cardiovas-
cular system. Circ Res. 2012;110(10):1364–90.
35. Gamez-Mendez AM, Vargas-Robles H, Rios A, Escalante B.
Oxidative stress-dependent coronary endothelial dysfunction in
obese mice. PLoS ONE. 2015;10(9), e0138609.
36. Liu CQ, Leung FP, Wong SL, Wong WT, Lau CW, Lu L, et al.
Thromboxane prostanoid receptor activation impairs endothelial
nitric oxide-dependent vasorelaxations: the role of Rho kinase.
Biochem Pharmacol. 2009;78(4):374–81.
37. Banerjee D, Mazumder S, Sinha AK. The role of inhibition of
nitric oxide synthesis in the aggregation of platelets due to the
stimulated production of thromboxane A2. Blood Coagul
Fibrinolysis: Int J Haemostasis Thrombosis. 2014;25(6):585–91.
38. Banerjee D, Mazumder S, Kumar Sinha A. Involvement of nitric
oxide on calcium mobilization and arachidonic acid pathway ac-
tivation during platelet aggregation with different aggregating ag-
onists. Int J Biomed Sci: IJBS. 2016;12(1):25–35.
39. Ellinsworth DC, Shukla N, Fleming I, Jeremy JY. Interactions
between thromboxane A(2), thromboxane/prostaglandin (TP) re-
ceptors, and endothelium-derived hyperpolarization. Cardiovasc
Res. 2014;102(1):9–16.
40. Vanhoutte PM. Endothelium-dependent contractions in hyperten-
sion: when prostacyclin becomes ugly. Hypertension. 2011;57(3):
526–31.
41. LuoW, Liu B, Zhou Y. The endothelial cyclooxygenase pathway:
insights from mouse arteries. Eur J Pharmacol. 2016;780:148–58.
42. Kirkby NS, Lundberg MH, Harrington LS, Leadbeater PD, Milne
GL, Potter CM, et al. Cyclooxygenase-1, not cyclooxygenase-2, is
responsible for physiological production of prostacyclin in the
cardiovascular system. Proc Natl Acad Sci U S A.
2012;109(43):17597–602.
43. Zhou Y, Luo W, Zhang Y, Li H, Huang D, Liu B. Cyclo-
oxygenase-1 or −2-mediated metabolism of arachidonic acid in
endothelium-dependent contraction of mouse arteries. Exp
Physiol. 2013;98(7):1225–34.
44. Patrono C. Cardiovascular effects of nonsteroidal anti-
inflammatory drugs. Curr Cardiol Rep. 2016;18(3):1–8.
45. Tang SY, Monslow J, Todd L, Lawson J, Pure E, FitzGerald GA.
Cyclooxygenase-2 in endothelial and vascular smooth muscle
cells restrains atherogenesis in hyperlipidemic mice. Circulation.
2014;129(17):1761–9.
46. Kirkby NS, Zaiss AK, Urquhart P, Jiao J, Austin PJ, Al-Yamani
M, et al. LC-MS/MS confirms that COX-1 drives vascular pros-
tacyclin whilst gene expression pattern reveals non-vascular sites
of COX-2 expression. PLoS ONE. 2013;8(7), e69524.
47. Liu B, Li Z, Zhang Y, Luo W, Zhang J, Li H, et al. Vasomotor
reaction to cyclooxygenase-1-mediated prostacyclin synthesis in
carotid arteries from two-kidney-one-clip hypertensive mice.
PLoS ONE. 2015;10(8), e0136738.
48. Li S, Liu B, Luo W, Zhang Y, Li H, Huang D, et al. Role of
cyclooxygenase-1 and −2 in endothelium-dependent contraction
of atherosclerotic mouse abdominal aortas. Clin Exp Pharmacol
Physiol. 2016;43(1):67–74.
49. Tang EH, Vanhoutte PM. Gene expression changes of prostanoid
synthases in endothelial cells and prostanoid receptors in vascular
smooth muscle cells caused by aging and hypertension. Physiol
Genomics. 2008;32(3):409–18.
50. Pratico D, Tillmann C, Zhang ZB, Li H, FitzGerald GA.
Acceleration of atherogenesis by COX-1-dependent prostanoid
formation in low density lipoprotein receptor knockout mice.
Proc Natl Acad Sci U S A. 2001;98(6):3358–63.
51. Feletou M, Verbeuren TJ, Vanhoutte PM. Endothelium-dependent
contractions in SHR: a tale of prostanoid TP and IP receptors. Br J
Pharmacol. 2009;156(4):563–74.
52. Liu B, LuoW, ZhangY, Li H, ZhuN, HuangD, et al. Involvement
of cyclo-oxygenase-1-mediated prostacyclin synthesis in the va-
soconstrictor activity evoked by ACh in mouse arteries. Exp
Physiol. 2012;97(2):277–89.
53. Liu D, Liu B, Luo W, Li H, Zhang Y, Zhou Y. A vasoconstrictor
response to COX-1-mediated prostacyclin synthesis in young rat
renal arteries that increases in prehypertensive conditions. Am J
Physiol Heart Circ Physiol. 2015;309(5):H804–11.
54. White SJ, Newby AC, Johnson TW. Endothelial erosion of
plaques as a substrate for coronary thrombosis. Thromb
Haemost. 2016;115(3):509–19.
55. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano
AL, et al. 2016 European Guidelines on cardiovascular disease
prevention in clinical practice. Eur Heart J. 2016.
56. Romero M, Leon-Gomez E, Lobysheva I, Rath G, Dogne JM,
Feron O, et al. Effects of BM-573 on endothelial dependent relax-
ation and increased blood pressure at early stages of atherosclero-
sis. PLoS ONE. 2016;11(3), e0152579.
57. Huang SW,KuoHL,HsuMT, Tseng YJ, Lin SW,Kuo SC, et al. A
novel thromboxane receptor antagonist, nstpbp5185, inhibits
platelet aggregation and thrombus formation in animal models.
Thrombosis Haemostasis. 2016;116(2).
58. Francois H, Makhanova N, Ruiz P, Ellison J, Mao L, Rockman
HA, et al. A role for the thromboxane receptor in L-NAME hy-
pertension. Am J Physiol Renal Physiol. 2008;295(4):F1096–102.
59. Cayatte AJ, Du Y, Oliver-Krasinski J, Lavielle G, Verbeuren TJ,
Cohen RA. The thromboxane receptor antagonist S18886 but not
aspirin inhibits atherogenesis in apo E-deficient mice: evidence
that eicosanoids other than thromboxane contribute to atheroscle-
rosis. Arterioscler Thromb Vasc Biol. 2000;20(7):1724–8.
60. Del Turco S, Basta G, Lazzerini G, Chancharme L, Lerond L, De
Caterina R. Involvement of the TP receptor in TNF-alpha-induced
endothelial tissue factor expression. Vasc Pharmacol. 2014;62(2):
49–56.
61. Sebekova K, Ramuscak A, Boor P, Heidland A, Amann K. The
selective TP receptor antagonist, S18886 (terutroban), attenuates
renal damage in the double transgenic rat model of hypertension.
Am J Nephrol. 2008;28(1):47–53.
62. Gelosa P, Sevin G, Pignieri A, Budelli S, Castiglioni L, Blanc-
Guillemaud V, et al. Terutroban, a thromboxane/prostaglandin en-
doperoxide receptor antagonist, prevents hypertensive vascular
hypertrophy and fibrosis. Am J Physiol Heart Circ Physiol.
2011;300(3):H762–8.
63. Gelosa P, Ballerio R, Banfi C, Nobili E, Gianella A, Pignieri A,
et al. Terutroban, a thromboxane/prostaglandin endoperoxide re-
ceptor antagonist, increases survival in stroke-prone rats by
preventing systemic inflammation and endothelial dysfunction:
comparison with aspirin and rosuvastatin. J Pharmacol Exp Ther.
2010;334(1):199–205.
64. Bousser MG, Amarenco P, Chamorro A, Fisher M, Ford I, Fox
KM, et al. Terutroban versus aspirin in patients with cerebral
83 Page 10 of 12 Curr Hypertens Rep (2016) 18: 83
ischaemic events (PERFORM): a randomised, double-blind,
parallel-group trial. Lancet (London, England). 2011;377(9782):
2013–22.
65. Bots ML, Ford I, Lloyd SM, Laurent S, Touboul PJ, Hennerici
MG. Thromboxane prostaglandin receptor antagonist and carotid
atherosclerosis progression in patients with cerebrovascular dis-
ease of ischemic origin: a randomized controlled trial. Stroke; J
Cerebral Circ. 2014;45(8):2348–53.
66. Chan MV, Knowles RBM, Lundberg MH, Tucker AT, Mohamed
NA, Kirkby NS, et al. P2Y12 receptor blockade synergizes strong-
ly with nitric oxide and prostacyclin to inhibit platelet activation.
Br J Clin Pharmacol. 2016;81(4):621–33.
67. Thomas MR, Storey RF. Effect of P2Y12 inhibitors on inflamma-
tion and immunity. Thromb Haemost. 2015;114(9):490–7.
68. Frey AJ, Ibrahim S, Gleim S, Hwa J, Smyth EM. Biased suppres-
sion of TP homodimerization and signaling through disruption of
a TM GxxxGxxxL helical interaction motif. J Lipid Res.
2013;54(6):1678–90.
69. Heiss EH, Dirsch VM. Regulation of eNOS enzyme activity by
posttranslational modification. Curr Pharm Des. 2014;20(22):
3503–13.
70. Jung SB, Kim CS, Naqvi A, Yamamori T, Mattagajasingh I,
Hoffman TA, et al. Histone deacetylase 3 antagonizes aspirin-
stimulated endothelial nitric oxide production by reversing
aspirin-induced lysine acetylation of endothelial nitric oxide syn-
thase. Circ Res. 2010;107(7):877–87.
71. Kabirian F, Amoabediny G, Haghighipour N, Salehi-Nik N,
Zandieh-Doulabi B. Nitric oxide secretion by endothelial cells in
response to fluid shear stress, aspirin, and temperature. J Biomed
Mater Res A. 2015;103(3):1231–7.
72. Ghosh R, Bank S, Maji UK, Bhattacharya R, Guha S, Khan NN,
et al. The effect of acetyl salicylic acid induced nitric oxide syn-
thesis in the normalization of hypertension through the stimulation
of renal cortexin synthesis and by the inhibition of dermcidin
isoform 2, a hypertensive protein production. Int J Biomed Sci:
IJBS. 2014;10(3):158–66.
73. Karmohapatra SK, Chakraborty K, Kahn NN, Sinha AK. The role
of nitric oxide in aspirin induced thrombolysis in vitro and the
purification of aspirin activated nitric oxide synthase from human
blood platelets. Am J Hematol. 2007;82(11):986–95.
74. Hennekens CH, Schneider WR, Pokov A, Hetzel S, Demets D,
Serebruany V, et al. A randomized trial of aspirin at clinically
relevant doses and nitric oxide formation in humans. J
Cardiovasc Pharmacol Ther. 2010;15(4):344–8.
75. Hetzel S, DeMets D, Schneider R, Borzak S, Schneider W,
Serebruany V, et al. Aspirin increases nitric oxide formation in
chronic stable coronary disease. J Cardiovasc Pharmacol Ther.
2013;18(3):217–21.
76. Schror K, Rauch BH. Aspirin and lipid mediators in the cardiovascu-
lar system. Prostaglandins Lipid Mediators. 2015;121(Pt A):17–23.
77. Romano M, Cianci E, Simiele F, Recchiuti A. Lipoxins and
aspirin-triggered lipoxins in resolution of inflammation. Eur J
Pharmacol. 2015;760:49–63.
78. Nascimento-Silva V, Arruda MA, Barja-Fidalgo C, Fierro IM.
Aspirin-triggered lipoxin A4 blocks reactive oxygen species gen-
eration in endothelial cells: a novel antioxidative mechanism.
Thromb Haemost. 2007;97(1):88–98.
79. Ho KJ, Spite M, Owens CD, Lancero H, Kroemer AH, Pande R,
et al. Aspirin-triggered lipoxin and resolvin E1 modulate vascular
smooth muscle phenotype and correlate with peripheral athero-
sclerosis. Am J Pathol. 2010;177(4):2116–23.
80. Vital SA, Becker F, Holloway PM, Russell J, Perretti M, Granger
DN, et al. Formyl-peptide receptor 2/3/Lipoxin a4 receptor regu-
lates neutrophil-platelet aggregation and attenuates cerebral in-
flammation: impact for therapy in cardiovascular disease.
Circulation. 2016;133(22):2169–79.
81. Gil-Villa AM, Norling LV, Serhan CN, Cordero D, Rojas M,
Cadavid A. Aspirin triggered-lipoxin A4 reduces the adhesion of
human polymorphonuclear neutrophils to endothelial cells initiat-
ed by preeclamptic plasma. Prostaglandins Leukot Essent Fat
Acids. 2012;87(4–5):127–34.
82. Ed Rainger G, Chimen M, Harrison MJ, Yates CM, Harrison P,
Watson SP, et al. The role of platelets in the recruitment of leuko-
cytes during vascular disease. Platelets. 2015;26(6):507–20.
83. Elajami TK, Colas RA, Dalli J, Chiang N, Serhan CN, Welty FK.
Specialized proresolving lipid mediators in patients with coronary
artery disease and their potential for clot remodeling. FASEB J :
Off Publ Fed Am Soc Exp Biol. 2016.
84. Dona M, Fredman G, Schwab JM, Chiang N, Arita M, Goodarzi
A, et al. Resolvin E1, an EPA-derived mediator in whole blood,
selectively counterregulates leukocytes and platelets. Blood.
2008;112(3):848–55.
85. Gong Y, Lin M, Piao L, Li X, Yang F, Zhang J, et al. Aspirin
enhances protective effect of fish oil against thrombosis and
injury-induced vascular remodelling. Br J Pharmacol.
2015;172(23):5647–60.
86. Mahajan-Thakur S, BohmA, Jedlitschky G, Schror K, Rauch BH.
Sphingosine-1-phosphate and its receptors: a mutual link between
blood coagulation and inflammation. Mediat Inflamm.
2015;2015:831059.
87. Vito CD, Hadi LA, Navone SE, Marfia G, Campanella R,
Mancuso ME, et al. Platelet-derived sphingosine-1-phosphate
and inflammation: from basic mechanisms to clinical implica-
tions. Platelets. 2016;27(5):393–401.
88. Pietri P, Vlachopoulos C, Terentes-Printzios D, Xaplanteris P,
Aznaouridis K, Petrocheilou K, et al. Beneficial effects of low-
dose aspirin on aortic stiffness in hypertensive patients. Vasc Med.
2014;19(6):452–7.
89. Soloviev MA, Kulakova NV, Semiglazova TA, Borodulina EV,
Udut VV. Correction of endothelial dysfunction in patients with
arterial hypertension. Bull Exp Biol Med. 2011;151(2):183–5.
90. Magen E, Viskoper JR, Mishal J, Priluk R, London D, Yosefy C.
Effects of low-dose aspirin on blood pressure and endothelial
function of treated hypertensive hypercholesterolaemic subjects.
J Hum Hypertens. 2005;19(9):667–73.
91. Hermida RC, Ayala DE, Calvo C, Lopez JE. Aspirin administered
at bedtime, but not on awakening, has an effect on ambulatory
blood pressure in hypertensive patients. J Am Coll Cardiol.
2005;46(6):975–83.
92. Hermida RC, Ayala DE, Mojon A, Fernandez JR. Ambulatory
blood pressure control with bedtime aspirin administration in sub-
jects with prehypertension. Am JHypertens. 2009;22(8):896–903.
93. Ayala DE, Hermida RC. Sex differences in the administration-
time-dependent effects of low-dose aspirin on ambulatory blood
pressure in hypertensive subjects. Chronobiol Int. 2010;27(2):
345–62.
94. Hermida RC, Ayala DE, Calvo C, Lopez JE, Mojon A, Rodriguez
M, et al. Differing administration time-dependent effects of aspirin
on blood pressure in dipper and non-dipper hypertensives.
Hypertension. 2005;46(4):1060–8.
95. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm
M, et al. 2013 ESH/ESCGuidelines for themanagement of arterial
hypertension. Eur Heart J. 2013;34(28):2159–219.
96. Bibbins-Domingo K. Aspirin use for the primary prevention of
cardiovascular disease and colorectal cancer: U.S. Preventive
Services Task Force Recommendation StatementAspirin Use for
the Primary Prevention of CVD and CRC. Ann Intern Med.
2016;164(12):836–45.
97. National Institute for Health and Care Excellence. Clinical
Knowledge Summaries. Antiplatelet treatment (Last revised in
October 2015). Scenario: Antiplatelet treatment for primary pre-
vention of cardiovascular disease (CVD). Available from
Curr Hypertens Rep (2016) 18: 83 Page 11 of 12 83
http://cks.nice.org.uk/antiplatelet-treatment#!scenario. Accessed
August 10, 2016.
98. Santilli F, Pignatelli P, Violi F, Davì G. Aspirin for primary pre-
vention in diabetes mellitus: from the calculation of cardiovascular
risk and risk/benefit profile to personalised treatment. Thromb
Haemost. 2015;114(11):876–82.
99. Kunutsor SK, Seidu S, Khunti K. Aspirin for primary prevention
of cardiovascular and all-cause mortality events in diabetes: up-
dated meta-analysis of randomized controlled trials. Diabetic
Med: J British Diabetic Assoc. 2016.
100. Bartolucci AA, Howard G. Meta-analysis of data from the six
primary prevention trials of cardiovascular events using aspirin.
Am J Cardiol. 2006;98(6):746–50.
101. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R,
et al. Aspirin in the primary and secondary prevention of vascular
disease: collaborative meta-analysis of individual participant data
from randomised tr ials . Lancet (London, England) .
2009;373(9678):1849–60.
102. Bartolucci AA, Tendera M, Howard G. Meta-analysis of multiple
primary prevention trials of cardiovascular events using aspirin.
Am J Cardiol. 2011;107(12):1796–801.
103. Raju N, Sobieraj-Teague M, Hirsh J, O’Donnell M, Eikelboom J.
Effect of aspirin on mortality in the primary prevention of cardio-
vascular disease. Am J Med. 2011;124(7):621–9.
104. Raju N, Sobieraj-Teague M, Bosch J, Eikelboom JW. Updated
meta-analysis of aspirin in primary prevention of cardiovascular
disease. Am J Med. 2016;129(5):e35–6.
105.• Guirguis-Blake JM, Evans CV, Senger CA, O’Connor EA,
Whitlock EP. Aspirin for the Primary Prevention of
Cardiovascular Events: A Systematic Evidence Review for the
U.S. Preventive Services Task ForceAspirin for the Primary
Prevention of Cardiovascular Events. Ann Intern Med.
2016;164(12):804–13. A systematic review of effectiveness of
aspirin for primary prevention of cardiovascular events.
106.• Whitlock EP, Burda BU, Williams SB, Guirguis-Blake JM, Evans
CV. Bleeding risks with aspirin use for primary prevention in
adults: a systematic review for the U.S. Preventive Services Task
Force Bleeding Risks With Aspirin Use. Ann Intern Med.
2016;164(12):826–35. A systematic review of safety of aspirin
for primary prevention of cardiovascular events.
107. Bayer. A Study to Assess the Efficacy and Safety of Enteric-
Coated Acetylsalicylic Acid in Patients at Moderate Risk of
Cardiovascular Disease (ARRIVE). July 12, 2007. Updated:
July 1, 2016. NLM Identifier: NCT00501059 Available from:
https://clinicaltrials.gov/ct2/show/NCT00501059. Accessed
July 30, 2016.
108. ASPREE Investigator Group. Study design of ASPirin in
Reducing Events in the Elderly (ASPREE): a randomized, con-
trolled trial. Contemp Clin Trials. 2013;36(2):555–64.
109. De Berardis G, Sacco M, Evangelista V, Filippi A, Giorda CB,
Tognoni G, et al. Aspirin and Simvastatin Combination for
Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-
D): design of a randomized study of the efficacy of low-dose
aspirin in the prevention of cardiovascular events in subjects with
diabetes mellitus treated with statins. Trials. 2007;8:21.
110. Aung T, Haynes R, Barton J, Cox J, Murawska A, Murphy K,
et al. Cost-effective recruitment methods for a large randomised
trial in people with diabetes: A Study of Cardiovascular Events iN
Diabetes (ASCEND). Trials. 2016;17(1):286.
111. Population Health Research Institute. The International Polycap
Study 3 (TIPS-3). July 10, 2012. Updated: May 22, 2015.
Available from: https://clinicaltrials.gov/ct2/show/NCT01646437.
Accessed July 28, 2016.
112. Le Quellec S, Bordet JC, Negrier C, Dargaud Y. Comparison of
current platelet functional tests for the assessment of aspirin and
clopidogrel response. A review of the literature. Thrombosis
Haemostasis. 2016(2016-07-21 00:00:00).
113. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin
Bresistance^ and risk of cardiovascular morbidity: systematic re-
view and meta-analysis. BMJ. 2008;336(7637):195–8.
114. Snoep JD, HovensMM, Eikenboom JC, van der Bom JG, Huisman
MV. Association of laboratory-defined aspirin resistance with a
higher risk of recurrent cardiovascular events: a systematic review
and meta-analysis. Arch Intern Med. 2007;167(15):1593–9.
115. Pettersen AA, Arnesen H, Seljeflot I. A brief review on high on-
aspirin residual platelet reactivity. Vasc Pharmacol. 2015;67–69:
6–9.
116. Nagatsuka K, Miyata S, Kada A, Kawamura A, Nakagawara J,
Furui E, et al. Cardiovascular events occur independently of high
on-aspirin platelet reactivity and residual COX-1 activity in stable
cardiovascular patients. Thrombosis Haemostasis. 2016;116(2).
117. Brun C, Daali Y, Combescure C, Zufferey A, Michelson AD,
Fontana P, et al. Aspirin response: Differences in serum thrombox-
ane B2 levels between clinical studies. Platelets. 2016;27(3):196–
202.
118. Homorodi N, Kovacs EG, Lee S, Katona E, Shemirani AH,
Haramura G, et al. The lack of aspirin resistance in patients with
coronary artery disease. J Transl Med. 2016;14:74.
119. FreynhoferMK, Gruber SC, Grove EL,Weiss TW,Wojta J, Huber
K. Antiplatelet drugs in patients with enhanced platelet turnover:
biomarkers versus platelet function testing. Thromb Haemost.
2015;114(9):459–68.
120. Kakouros N, Nazarian SM, Stadler PB, Kickler TS, Rade JJ. Risk
factors for nonplatelet thromboxane generation after coronary ar-
tery bypass graft surgery. J Am Heart Assoc. 2016;5(3), e002615.
121. Christensen KH, Grove EL, Wurtz M, Kristensen SD, Hvas AM.
Reduced antiplatelet effect of aspirin during 24 hours in patients
with coronary artery disease and type 2 diabetes. Platelets.
2015;26(3):230–5.
122. Henry P, Vermillet A, Boval B, Guyetand C, Petroni T, Dillinger
JG, et al. 24-hour time-dependent aspirin efficacy in patients with
stable coronary artery disease. Thromb Haemost. 2011;105(2):
336–44.
123. Larsen SB, Grove EL, Neergaard-Petersen S,WurtzM, Hvas AM,
Kristensen SD. Determinants of reduced antiplatelet effect of as-
pirin in patients with stable coronary artery disease. PLoS ONE.
2015;10(5), e0126767.
124.• Doroszko A, Szahidewicz-Krupska E, Janus A, Jakubowski M,
Turek A, Ilnicka P, et al. Endothelial dysfunction in young healthy
men is associated with aspirin resistance. Vasc Pharmacol.
2015;67–69:30–7. A study showing association between endo-
thelial function and effectivenes of aspirin therapy.
125.• Larsen SB, Grove EL,WurtzM, Neergaard-Petersen S, Hvas AM,
Kristensen SD. The influence of low-grade inflammation on plate-
lets in patients with stable coronary artery disease. Thromb
Haemost. 2015;114(3):519–29. A study showing impact of vas-
cular inflammation on platelets aggregation.
126. Stratz C, Nuehrenberg T, Amann M, Cederqvist M, Kleiner P,
Valina CM, et al. Impact of reticulated platelets on antiplatelet
response to thienopyridines is independent of platelet turnover.
Thrombosis Haemostasis. 2016(2016-08-04 00:00:00).
83 Page 12 of 12 Curr Hypertens Rep (2016) 18: 83
